Video

Dr. Swords on Anti-Tumor Effects of IMG-98 in AML

Ronan T. Swords, MD, discusses preclinical findings demonstrating that the small-molecule inhibitor IMG-98 effectively augments pro-differentiation effects of all-trans-retinoic acid–based therapies in acute myeloid leukemia.

Ronan T. Swords, MD, PhD, FRCPI, FRCPath, co-leader of the Leukemia/Lymphoma/Myeloma Site Disease Group at Sylvester Comprehensive Cancer at the University of Miami Miller School of Medicine, discusses preclinical findings demonstrating that the small-molecule inhibitor IMG-98 effectively augments pro-differentiation effects of all-trans-retinoic acid (ATRA)—based therapies in acute myeloid leukemia (AML).

Previous studies have shown the efficacy of tranylcypromine (TCP) combined with ATRA in patients with AML, Swords explains. However, the conflict with using TCP as an LSD-1 inhibitor is that it is neither potent nor selective.

In this preclinical study, IMG-98, another LSD-1 inhibitor, was found to augment ATRA pro-differentiation effects. IMG-98 binds with FAD, and when combined with ATRA, it activates the retinoic-acid signaling pathway. In conclusion, this regimen was found to potently induce more differentiation versus ATRA alone, Swords says.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity